Suchen
Ocugen Inc
OCGNZur Watchlist hinzufügen
1.390USD
-0.070-4.79%
Handelsschluss 05/15, 16:00（ET）Kurse um 15 Minuten verzögert
470.55MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Ocugen Inc Unternehmen
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. Its technology pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, and Inhaled Mucosal Vaccine Platform. It is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal diseases, including retinitis pigmentosa, Leber congenital amaurosis, Stargardt disease and multifactorial diseases, such as dry age-related macular degeneration (dAMD) and geographic atrophy. It is developing a next-generation, inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine, and OCU520, a combination quadrivalent seasonal flu.
Ocugen Inc Informationen
BörsenkürzelOCGN
Name des UnternehmensOcugen Inc
IPO-datumDec 03, 2014
CEOMusunuri (Shankar)
Anzahl der mitarbeiter95
WertpapierartOrdinary Share
GeschäftsjahresendeDec 03
Addresse11 Great Valley Parkway
StadtMALVERN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl19355
Telefon14843284701
Websitehttps://ocugen.com/
BörsenkürzelOCGN
IPO-datumDec 03, 2014
CEOMusunuri (Shankar)
Führungskräfte von Ocugen Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
+14.27%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
--
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
-11516.67%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Ms. Tiffany Hamilton
Ms. Tiffany Hamilton
Head of Communications
Head of Communications
--
--
Dr. Huma Qamar, M.D.
Dr. Huma Qamar, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Junge Zhang, Ph.D.
Mr. Junge Zhang, Ph.D.
Independent Director
Independent Director
1.36M
+14.27%
Dr. Arun Upadhyay, Ph.D.
Dr. Arun Upadhyay, Ph.D.
Chief Scientific Officer, Head of Research and Development
Chief Scientific Officer, Head of Research and Development
214.50K
--
Mr. Ramesh Ramachandran, CPA
Mr. Ramesh Ramachandran, CPA
Chief Accounting Officer
Chief Accounting Officer
1.80K
-11516.67%
Dr. Shankar Musunuri, Ph.D.
Dr. Shankar Musunuri, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Uday B. Kompella, Ph.D.
Dr. Uday B. Kompella, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kirsten Castillo
Ms. Kirsten Castillo
Independent Director
Independent Director
--
--
Umsatzaufteilung
FY2025
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2021
FY2020
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Nach RegionUSD
Name
Umsatz
Anteil
United States
4.41M
0.00%
Nach Geschäftsbereich
Nach Region
Relevante Daten wurden vom Unternehmen noch nicht offengelegt.
Aktionärsstatistik
Aktualisiert: Sun, May 10
Aktualisiert: Sun, May 10
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Millennium Management LLC
5.04%
Vanguard Capital Management, LLC
4.08%
UBS Financial Services, Inc.
2.14%
BlackRock Institutional Trust Company, N.A.
1.27%
State Street Investment Management (US)
1.18%
Andere
86.29%
Aktionäre
Aktionäre
Anteil
Millennium Management LLC
5.04%
Vanguard Capital Management, LLC
4.08%
UBS Financial Services, Inc.
2.14%
BlackRock Institutional Trust Company, N.A.
1.27%
State Street Investment Management (US)
1.18%
Andere
86.29%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
10.49%
Hedge Fund
6.69%
Investment Advisor/Hedge Fund
3.61%
Research Firm
1.48%
Individual Investor
1.34%
Corporation
0.34%
Pension Fund
0.15%
Venture Capital
0.10%
Bank and Trust
0.01%
Andere
75.77%
Institutionelle Beteiligung
Aktualisiert: Wed, Apr 1
Aktualisiert: Wed, Apr 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2026Q1
276
81.01M
24.06%
+20.94K
2025Q4
260
72.53M
22.12%
+9.34M
2025Q3
255
51.36M
16.44%
-32.04M
2025Q2
268
78.45M
26.84%
-13.23M
2025Q1
278
81.07M
27.89%
-11.63M
2024Q4
292
76.62M
26.34%
-21.25M
2024Q3
306
84.66M
29.43%
-6.14M
2024Q2
300
72.04M
27.84%
+19.28M
2024Q1
302
36.88M
14.47%
-15.26M
2023Q4
300
30.54M
12.06%
-31.79M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Millennium Management LLC
5.40M
1.65%
+1.23M
+29.65%
Dec 31, 2025
UBS Financial Services, Inc.
4.68M
1.43%
+3.84M
+456.44%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
4.30M
1.31%
+475.52K
+12.43%
Dec 31, 2025
State Street Investment Management (US)
3.98M
1.21%
+2.62M
+193.55%
Dec 31, 2025
Geode Capital Management, L.L.C.
3.82M
1.16%
+142.05K
+3.86%
Dec 31, 2025
Jane Street Capital, L.L.C.
1.69M
0.52%
+816.55K
+93.26%
Dec 31, 2025
Marshall Wace LLP
2.53M
0.77%
+2.53M
--
Dec 31, 2025
Goldman Sachs & Company, Inc.
2.22M
0.68%
+2.20M
+10494.89%
Dec 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Dec 2
Aktualisiert: Tue, Dec 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.82%
Pacer WealthShield ETF
0%
iShares Russell 2000 ETF
0%
iShares Micro-Cap ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.82%
Pacer WealthShield ETF
Anteil0%
iShares Russell 2000 ETF
Anteil0%
iShares Micro-Cap ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
ProShares Hedge Replication ETF
Anteil0%
iShares Core S&P Total U.S. Stock Market ETF
Anteil0%
iShares Russell 2000 Growth ETF
Anteil0%
Global X Russell 2000 ETF
Anteil0%
Proshares Ultra Russell 2000
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
Datum
Ex-Dividendentag
Art
Verhältnis
Keine Daten
